Table 7.
The 3-year OS, LRFS, DMFS, and PFS in the VEGF –460T/C genotype subgroups after chemotherapy regimens
| –460T/C genotype | 3-year OS
|
P-value | 3-year LRFS
|
P-value | 3-year DMFS
|
P-value | 3-year PFS
|
P-value | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NACT + CCRT | CCRT | NACT + CCRT | CCRT | NACT + CCRT | CCRT | NACT + CCRT | CCRT | |||||
| T/T | 93.9% | 95.9% | 0.707 | 88.0% | 96.1% | 0.173 | 84.7% | 96.2% | 0.238 | 84.9% | 87.9% | 0.754 |
| T/C | 79.5% | 74.6% | 0.700 | 96.0% | 94.7% | 0.7815 | 81.8% | 78.1% | 0.587 | 63.3% | 75.7% | 0.420 |
| C/C | 85.7% | 87.5% | 0.881 | 85.7% | 100.0% | 0.285 | 85.7% | 75.0% | 0.962 | 85.7% | 87.5% | 0.922 |
| T/C + C/C | 80.9% | 80.0% | 0.720 | 93.6% | 95.6% | 0.760 | 83.1% | 76.8% | 0.597 | 68.4% | 77.8% | 0.469 |
Note: P<0.05 was considered statistically significant.
Abbreviations: CCRT, concurrent chemoradiotherapy; DMFS, distant metastasis-free survival; LRFS, local recurrence-free survival; NACT, neoadjuvant chemotherapy; OS, overall survival; PFS, progression-free survival; VEGF, vascular endothelial growth factor.